Test Price
4,000 AED✅ Home Collection Available
Lung Cancer Panel 4: EGFR, ALK, ROS1, MET & PD‑L1 in UAE | 4,000 AED | DHA Licensed
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
- Sample Collection: Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance for Result Interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
This integrated molecular panel assesses five actionable biomarkers from a single tumor tissue specimen, enabling precision targeted therapy and immunotherapy decisions for non-small cell lung cancer. Results are correlated with histopathology and clinical staging per international guidelines.
Test Overview & Methodology
The Lung Cancer Panel 4 is a comprehensive molecular diagnostic test that simultaneously evaluates five critical biomarkers – EGFR, ALK, ROS1, MET, and PD‑L1 – from a single tumor tissue sample, enabling oncologists to prescribe the most effective targeted therapy or immunotherapy for non-small cell lung cancer. DNA Labs UAE employs gold-standard Sanger sequencing, fluorescence in-situ hybridization, and immunohistochemistry to deliver high-confidence results with rapid turnaround.
| Feature | DNA Labs UAE (Our Test) | Closest Alternative (Generic NGS Panel) |
|---|---|---|
| Methodology | Sanger Sequencing + FISH + Immunohistochemistry (PD‑L1) | Next‑Generation Sequencing (may miss some gene fusions) |
| Genes Covered | EGFR (mutations), ALK, ROS1, MET (fusions/amplifications), PD‑L1 (expression) | Often limited to mutational hotspots; fusions require separate FISH |
| Turnaround Time | 5–7 business days | 10–14 business days |
| Price | 4,000 AED (hospital logistics included) | 4,500–5,500 AED (sample logistics extra) |
| DHA/MOHAP Compliance | Full; ISO 9001:2015 compliant with UAE healthcare regulations | Variable |
Physician Insight & Safety Protocols
“This panel delivers clinically actionable information; however, results must be interpreted in the full context of the patient’s histology, stage, and performance status. I strongly advise that no treatment decision be made solely on a single biomarker result – multidisciplinary tumor board discussion is essential for optimal care.”
— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011
Advisory Notice
Do not alter or discontinue any prescribed medication without consulting your treating physician. Laboratory results should complement, not replace, comprehensive clinical evaluation.
Exclusion Criteria & Emergency Red Flags
- Insufficient tumor tissue (minimum 10% tumor nuclei content required).
- Known severe bleeding disorder – inform the treating physician before biopsy.
- Pregnancy is not a contraindication for the test, but discuss with your physician.
Emergency Red Flags: If you experience coughing up blood, sudden chest pain, or difficulty breathing, seek emergency care immediately.
Patient FAQ & Clinical Guidance
1. Why is this lung cancer panel important for treatment selection?
Direct Answer: This panel identifies actionable mutations in EGFR, ALK, ROS1, MET, and PD‑L1 for targeted therapy selection. By detecting specific genetic alterations, oncologists can match patients to FDA‑approved or DHA‑endorsed tyrosine kinase inhibitors or immunotherapies, significantly improving progression‑free survival while avoiding ineffective chemotherapy. The comprehensive five-marker approach reduces the need for sequential single-gene testing, conserving tissue and accelerating time to treatment.
2. How is the sample collected?
Direct Answer: A small tumor tissue sample is required and must be obtained via biopsy performed at an accredited hospital facility. Tissue slides or FFPE blocks stored at a pathology laboratory can be transferred using a certified medical courier for archival analysis. Hospital extraction only – mobile home phlebotomy is not available for this test due to the invasive nature of tissue biopsy. No special preparation is needed beyond your clinician’s pre‑biopsy instructions.
3. What is PD‑L1 testing and why is it included?
Direct Answer: PD‑L1 expression predicts response to immunotherapy, guiding checkpoint inhibitor use in lung cancer. This immunohistochemical assay measures the percentage of tumor cells expressing PD‑L1 protein; a high score (≥50%) may qualify the patient for first‑line pembrolizumab monotherapy, while lower levels might require combination chemotherapy plus immunotherapy. Including PD‑L1 in this panel eliminates the need for a separate immunohistochemistry order and ensures coordinated reporting with mutational status.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance & Data Protection:
All laboratory services are conducted in strict compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical testing safety and patient consent protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. DNA Labs UAE holds ISO 9001:2015 certification (INT/EGQ/2509DA/3139) and operates under DHA Facility License 1143. Test results are intended for clinical interpretation by a licensed physician and do not substitute for professional medical advice.
Clinical & Logistical Metadata
| Test Name | Lung Cancer Panel 4 (EGFR, ALK, ROS1, MET & PD‑L1) |
| Price (AED) | 4,000 AED |
| Turnaround Time | 5–7 business days |
| Sample Type / Matrix | Tumor Tissue (FFPE Block or Biopsy Slides) |
| Methodology Used | Sanger Sequencing, FISH, Immunohistochemistry |
| ICD-10-CM Code | C34.9 |
| LOINC Code | 60513-6 |
| DHA Facility License & Laboratory Address | License 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians